Intrinsic resistance to chemotherapy in breast cancer

Stacy Moulder1

  • 1Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. smoulder@mdanderson.org

Insights

Systemic therapy offers limited benefits for advanced breast cancer and fails many localized cases. Research is exploring ways to overcome chemotherapy resistance, with new drugs in clinical trials.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Systemic therapy improves survival in breast cancer but does not cure advanced disease.
  • Chemotherapy resistance is a major cause of treatment failure in breast cancer.
  • Mechanisms of resistance include drug efflux pumps, apoptosis dysregulation, and cancer stem cells.

Purpose of the Study:

  • To investigate the causes of intrinsic chemotherapy resistance in breast cancer.
  • To explore novel therapeutic strategies targeting resistance mechanisms.

Main Methods:

  • Review of preclinical models and existing research on chemotherapy resistance.
  • Identification of key molecular mechanisms contributing to resistance.
  • Analysis of ongoing clinical trials for drugs targeting resistance.

Main Results:

  • Intrinsic resistance significantly impacts treatment outcomes in breast cancer.
  • Several molecular targets and pathways are implicated in chemotherapy resistance.
  • Clinical trials are evaluating drugs designed to reverse these resistance mechanisms.

Conclusions:

  • Overcoming chemotherapy resistance is crucial for improving breast cancer treatment efficacy.
  • Targeting resistance mechanisms holds promise for future breast cancer therapies.
  • Ongoing clinical investigations are vital for advancing treatment options.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...